

Fauske & Assoc

[View the current Fauske & Assoc Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/34025-Fauske+%26+Assoc.html)

(<http://www.bioportfolio.com/biocorporate/34025-Fauske+%26+Assoc.html>)

Contact Details:

16W070 W83Rd St

Burr Ridge

IL

60527

United States of America

Tel:

Fax:

Email:

Recent Publications by Fauske & Assoc:



- [Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms.](#)
*BACKGROUND & AIMS: Current guidelines recommend empirical, noninvasive...*27th August, 2009
University of Wisconsin School of Medicine and Public Health, Madison,- Clin Gastroenterol Hepatol. 2009 Jul;7(7):756-61. Epub 2009 Apr 10. ([DOI Direct Link](#))
- [Measuring case managers' advance care planning practice: translating focus group findings to survey development.](#)
*Sequential mixed methods is a useful research design to inform...*21st February, 2009
School of Social Work, University of South Florida at Sarasota/Manatee,- Care Manag J. 2008;9(4):166-76.
- [A 2.1 Mb deletion adjacent but distal to a 14q21q23 paracentric inversion in a family with spherocytosis and severe learning difficulties.](#)
*A familial q21.1q23.2-inversion on chromosome 14 that co-segregated with...*5th February, 2009
Center for Medical Genetics and Molecular Medicine, Haukeland University- Clin Genet. 2008 Dec;74(6):553-9. Epub 2008 Aug 18. ([DOI Direct Link](#))
- [Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.](#)
*BACKGROUND: The optimal combination drug therapy for hypertension is not...*17th December, 2008
Division of Cardiovascular Medicine, University of Michigan Health System,- N Engl J Med. 2008 Dec 4;359(23):2417-28. ([DOI Direct Link](#))
- [Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.](#)
*BACKGROUND: Increased levels of the inflammatory biomarker...*17th December, 2008

Center for Cardiovascular Disease Prevention, Brigham and Women's- N Engl J Med. 2008 Nov 20;359(21):2195-207. Epub 2008 Nov 9. ([DOI Direct Link](#))

- [Total flammable mass and volume within a vapor cloud produced by a continuous fuel-gas or volatile liquid-fuel release.](#)

The top-hat jet/plume model has recently been employed to obtain simple... 7th December, 2007
Fauske & Associates, LLC, 16W070 West 83rd Street, Burr Ridge, IL 60527,- J Hazard Mater. 2007 Aug 25;147(3):1037-50. Epub 2007 Feb 6. ([DOI Direct Link](#))

- [Exploring influences on community-based case managers' advance care planning practices: facilitators or barriers?](#)

Community-based geriatric case managers work with an increasingly frail... 4th July, 2007
School of Social Work, College of Education, University of South- Home Health Care Serv Q. 2007;26(2):41-58.

- [Complete mutation screening and haplotype characterization of the BRCA1 gene in 61 familial breast cancer patients from Norway.](#)

Mutations in the Breast-Cancer-1 (BRCA1) gene are the major cause of... 19th August, 2005
Center for Medical Genetics and Molecular Medicine, Haukeland University- Dis Markers. 2005;21(1):29-36.

- [Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?](#)

Carisoprodol is metabolized to meprobamate by the cytochrome P450 enzyme... 15th April, 2004
Norwegian Institute of Public Health, Division of Forensic Toxicology and- Pharmacogenetics. 2003 Jul;13(7):383-8. ([DOI Direct Link](#))

Press Releases on Fauske & Assoc:

[ChangeWave Issues Buy Recommendation on Access Pharmaceuticals](#)

17th November, 2009

Access Pharmaceuticals, Inc.

DALLAS, Nov. 17 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced that a recommendation report was issued by ChangeWave, a research network that

[Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America](#)

11th November, 2009

Access Pharmaceuticals, Inc.

-- Co-Promotion: Access continues to seek potential co-promotion arrangements with pharmaceutical and biotechnology companies in the oncology and oncology supportive care fields.

Whistleblower Retaliation Lawsuit Filed Against Carle Cancer Doctors and Executives in Connection with Violations of the Federal Safety Laws Protecting Patients in Experimental Clinical Cancer Trials	6th November, 2009	Katz, Marshall & Banks, LLP	<i>URBANA, Ill., Nov. 6 /PRNewswire/ -- Dr. Suzanne Stratton, the former Vice President for Research at the Carle Foundation Hospital in Urbana, IL, filed a whistleblower lawsuit yesterday in federal</i>
Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed	20th October, 2009	National Dairy Council	<i>-- Aged cheeses like Swiss, Parmesan, Gouda, Colby, provolone, Cheddar, Edam, Fontina, Gruyere, Muenster and Monterey Jack have very little lactose. For more</i>
Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)	6th October, 2009	Access Pharmaceuticals, Inc.	<i>DALLAS, Oct. 6 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it had signed an agreement with iMedicor (OTC Bulletin Board: VMCI) for the North</i>

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

